Three things you should know when considering the atria: location, location, location.
Boyden
P A
PA
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D001281:Atrial Fibrillation / Q000145:classification / Q000473:pathology / Q000503:physiopathology*; D002304:Cardiac Pacing, Artificial; D027682:Cation Transport Proteins; D002908:Chronic Disease; D004268:DNA-Binding Proteins; D018450:Disease Progression; D004285:Dogs; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; D006325:Heart Atria / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology*; D006329:Heart Conduction System / Q000187:drug effects / Q000503:physiopathology; D051379:Mice; D010627:Phenethylamines / Q000494:pharmacology; D026902:Potassium Channel Blockers; D015221:Potassium Channels / Q000378:metabolism; D024642:Potassium Channels, Voltage-Gated; D051381:Rats; D013449:Sulfonamides / Q000494:pharmacology; D015534:Trans-Activators
D000889:Anti-Arrhythmia Agents; D027682:Cation Transport Proteins; D004268:DNA-Binding Proteins; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; C092509:KCNH6 protein, human; D010627:Phenethylamines; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated; D013449:Sulfonamides; D015534:Trans-Activators; C059983:potassium channel protein I(sk); C063533:dofetilide